A single 300 mg dose of a new nanodispersible CBD solution showed 3-fold higher blood levels when taken with food compared to fasting, confirming that meal timing dramatically affects CBD absorption.
Anyone taking CBD products, pharmacologists studying cannabinoid formulations, clinicians prescribing CBD-based medications.
What the researchers found
In a randomized trial with 18 healthy male subjects, a novel nanodispersible CBD oral solution (150 mg/mL) was tested under fasting and fed conditions. Each participant received a single 300 mg dose.
The fed state tripled the total CBD exposure: the area under the curve (AUC) increased 3.0-fold compared to fasting (p < 0.0001). Peak blood concentration (Cmax) was moderately higher in the fed state (1.3-fold), and the time to reach peak concentration (Tmax) was prolonged — meaning the body absorbed more CBD overall when food was present, though it took longer to reach the peak.
The study also tracked CBD's metabolites. 7-COOH-CBD (7-carboxy-cannabidiol) reached the highest plasma concentration of any compound measured, followed by CBD itself and then 7-OH-CBD. This metabolite profile is relevant because 7-OH-CBD is pharmacologically active and may contribute to CBD's therapeutic effects.
Why it matters
CBD's poor and variable oral bioavailability is one of the biggest practical challenges in cannabinoid therapeutics. Understanding how food affects absorption is directly relevant to dosing — a 3-fold difference in blood levels depending on meal timing means the same dose could be sub-therapeutic when fasting or potentially cause more side effects when taken with food. The nanodispersible formulation represents an attempt to improve on this, though the food effect persisted.
The numbers in context
18 subjects, single 300 mg dose. Fed vs. fasting: AUC increased 3.0-fold (p < 0.0001), Cmax increased 1.3-fold, Tmax prolonged. 7-COOH-CBD reached highest plasma concentrations, followed by CBD, then 7-OH-CBD.
How the study worked
Randomized, single-dose, two-arm (fasting and fed), open-label pharmacokinetic trial. 18 healthy male subjects (9 per arm) received 300 mg of nanodispersible CBD oral solution. Plasma concentrations of CBD and metabolites (7-OH-CBD, 7-COOH-CBD) were quantified at multiple timepoints. Pharmacokinetic parameters analyzed using non-compartmental modeling.
Who was studied
N=18 healthy male subjects, randomized into fasting and fed groups.
What this study cannot tell us
Small sample (18 subjects, 9 per arm). Male subjects only — sex differences in CBD pharmacokinetics were not assessed. Single-dose study doesn't capture steady-state kinetics from repeated dosing. Healthy volunteers may not reflect pharmacokinetics in patient populations. The nanodispersible formulation is specific to this manufacturer.
How to read the evidence
Small randomized pharmacokinetic trial — rigorous design for measuring blood levels but limited by small sample size and single-dose protocol.
When this study was published
Published in 2026, testing a novel nanodispersible CBD formulation that represents the current frontier of cannabinoid drug delivery.
The bigger picture
This food effect is consistent with what's known about Epidiolex (FDA-approved CBD) and other lipophilic cannabinoids — they're absorbed much better with dietary fat. The nanodispersible formulation was designed to improve bioavailability, but the persistent 3-fold food effect suggests this challenge isn't fully solved. For anyone taking CBD therapeutically, these findings reinforce that consistent dosing relative to meals matters more than most people realize.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- How does this nanodispersible formulation compare to standard CBD oil in terms of bioavailability? Would female subjects show the same food effect magnitude? Does the 3-fold difference in absorption translate to a proportional difference in clinical effects?
Read the original research
A Randomized, Single-Dose, Single-Sequence, Two-Arm (Fasting and Fed), Open-Label Study on the Oral Pharmacokinetics of a Nanodispersible Cannabidiol Solution (150 mg/mL).
Medical cannabis and cannabinoids, 9(1), 20-29
Medical Cannabis and Cannabinoids is a peer-reviewed journal focusing on research related to cannabis and its medical applications.
Citation
Gundugurti, Prasad Rao; Nadikudi, Monila; Thatikonda, Ramyasree; Banda, Nagaraju; Yadlapalli, Siva Sankara Rao; Narala, Arjun; Kocherlakota, Chandrashekhar; Kothapalli, Kumar S D. (2026). A Randomized, Single-Dose, Single-Sequence, Two-Arm (Fasting and Fed), Open-Label Study on the Oral Pharmacokinetics of a Nanodispersible Cannabidiol Solution (150 mg/mL).. Medical cannabis and cannabinoids, 9(1), 20-29. https://doi.org/10.1159/000550104
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk